Products
Pre-Made Onfekafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) - trimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCFfor drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-936
Pre-Made Onfekafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) - trimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCFis a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
ED-B is predominantly expressed during angiogenesis and tumor growth. Onfekafusp Alfa is an immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-936-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-936-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-936-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-936-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Recombinant therapeutic protein targeting FN/FN1 fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) - trimer (Pre-made Onfekafusp Alfa biosimilar, Fusion Protein) |
| INN Name | Onfekafusp Alfa |
| Target | FN/FN1 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | [scFv - heavy - kappa] - trimer |
| VD LC | [scFv - heavy - kappa] - trimer |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Philogen (Sovicille Italy) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
